

**FORM 51-102F3
MATERIAL CHANGE REPORT
UNDER NATIONAL INSTRUMENT 51-102**

Item 1 Name and Address of Company

Abattis Bioceuticals Corp. (the "Issuer")
104 - 9295 198th Street,
Langley, B.C., V1M 3J9

Item 2 Date of Material Change

November 2, 2016

Item 3 News Release

A news release was disseminated on November 2, 2016 through the facilities of NewsFile and subsequently filed on SEDAR.

Item 4 Summary of Material Change

On November 2, 2016 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT) announced the appointment of Dr. William Panenka to the Board of Directors.

Item 5 Full Description of Material Change

On November 2, 2016 Abattis announced the appointment of Dr. William Panenka to the Board of Directors.

Dr. Panenka received his M.D. and M.Sc. from the University of Calgary in Canada. His M.Sc. was basic science-focused utilizing Western Blotting, PCR, in-situ hybridization and other wet lab techniques. He completed residencies in both psychiatry and neurology at the University of British Columbia in Vancouver, Canada.

In 2011 Dr. Panenka began a research fellowship focusing on the mental and physical health, as well as the brain imaging correlates of drug use and addictions. In 2012, he became a research fellow at Harvard University and was competitively recruited to the University of British Columbia in 2013 as an assistant professor in psychiatry. His main focus is addiction and traumatic brain injury, with multiple basic science and clinical collaborations nationally and internationally.

Dr. Panenka is currently a co-investigator on several clinical studies involving Cannabis, focusing on the effects of THC and CBD on psychosis, mood and anxiety. In collaboration with a local biotech start-up company, his team at UBC was recently awarded a MITACS industry-academic partnership grant to partially fund this research.

According to Rene David, CFO and acting CEO of Abattis Bioceuticals, "We are extremely pleased Dr. Panenka has agreed to join our board as an independent director. He provides us with a wealth of knowledge and experience as a clinician, researcher and professor and welcome his input with respect to our nutraceutical product lines and controlled substances testing facility. We look forward to his guidance as Abattis and subsidiaries navigate the legal cannabis industry."

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

N/A

Item 7 Omitted Information

N/A

Item 8 Executive Officer

Rene David

CFO

Abattis Bioceuticals Corp.

Tel: 604.336.0881

Item 9 Date of Report

November 17, 2016

Cautionary Note Regarding Forward Looking Statements

This material change report contains certain forward-looking statements about the Company's future plans and intentions, including statements relating to the Company's intention to implement changes across its business to achieve growth. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "scheduled" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect Management's current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.